Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives $107.10 Consensus PT from Brokerages

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) have earned a consensus rating of "Buy" from the eleven analysts that are covering the stock, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $107.10.

A number of analysts recently commented on the company. Guggenheim increased their price objective on Soleno Therapeutics from $81.00 to $97.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Laidlaw lifted their price target on shares of Soleno Therapeutics from $75.00 to $105.00 and gave the stock a "buy" rating in a report on Thursday, March 27th. Robert W. Baird boosted their price objective on shares of Soleno Therapeutics from $102.00 to $105.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. UBS Group set a $105.00 target price on shares of Soleno Therapeutics in a research report on Thursday, March 27th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $100.00 target price on shares of Soleno Therapeutics in a research note on Tuesday, April 15th.

Insider Buying and Selling at Soleno Therapeutics

In other Soleno Therapeutics news, insider Patricia C. Hirano sold 3,830 shares of the firm's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $82.76, for a total value of $316,970.80. Following the transaction, the insider owned 13,206 shares of the company's stock, valued at $1,092,928.56. This trade represents a 22.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 6.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Soleno Therapeutics

Several hedge funds have recently made changes to their positions in the stock. AlphaQuest LLC increased its position in Soleno Therapeutics by 1,154.4% in the fourth quarter. AlphaQuest LLC now owns 715 shares of the company's stock worth $32,000 after buying an additional 658 shares during the period. US Bancorp DE acquired a new stake in shares of Soleno Therapeutics in the 4th quarter worth about $34,000. Quarry LP bought a new stake in Soleno Therapeutics in the 1st quarter valued at about $121,000. Springhill Fund Asset Management HK Co Ltd acquired a new position in Soleno Therapeutics during the 4th quarter valued at about $81,000. Finally, Avanza Fonder AB grew its position in Soleno Therapeutics by 14.8% in the 1st quarter. Avanza Fonder AB now owns 1,951 shares of the company's stock worth $144,000 after purchasing an additional 251 shares during the last quarter. Institutional investors own 97.42% of the company's stock.

Soleno Therapeutics Stock Performance

Shares of NASDAQ:SLNO traded down $8.17 during trading on Wednesday, reaching $80.32. The company had a trading volume of 5,643,161 shares, compared to its average volume of 818,885. Soleno Therapeutics has a fifty-two week low of $41.50 and a fifty-two week high of $90.79. The company has a debt-to-equity ratio of 0.21, a current ratio of 19.64 and a quick ratio of 19.64. The stock's fifty day moving average price is $78.61 and its 200 day moving average price is $62.17. The firm has a market capitalization of $4.05 billion, a price-to-earnings ratio of -17.39 and a beta of -2.63.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.14) by $0.19. As a group, equities research analysts predict that Soleno Therapeutics will post -3.72 EPS for the current year.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.